Phil McEwan

Summary

Affiliation: University of Wales
Country: UK

Publications

  1. doi request reprint The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States
    Phil McEwan
    Centre for Health Economics, Swansea University, Wales, UK Health Economics and Outcomes Research Ltd, Wales, UK
    Hepatology 58:54-64. 2013
  2. doi request reprint Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
    Phil McEwan
    Centre for Health Economics, Swansea University, Wales, UK
    Appl Health Econ Health Policy 11:53-63. 2013
  3. doi request reprint Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
    Phil McEwan
    Health Economics and Outcomes Research, Monmouth, Wales, UK
    Hepatol Res 46:423-33. 2016
  4. doi request reprint Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C
    Rebecca Townsend
    Cardiff Research Consortium, Cardiff, Wales, UK
    Value Health 14:1068-77. 2011
  5. doi request reprint Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration
    Phil McEwan
    Swansea Centre for Health Economics, Swansea University, Wales, UK PCM, HB Health Economics and Outcomes Research Ltd, Wales, UK PCM, JG, TW University Health Board, Llandough, Wales, UK ME Global Health Economics and Outcomes Research, AstraZeneca, Molndal, Sweden KB Department of Public Health, University of Adelaide, South Australia, Australia JG
    Med Decis Making 35:660-70. 2015
  6. pmc Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C
    Phil McEwan
    HEOR Ltd, Singleton Court Business Park, Monmouth, Wales, United Kingdom Swansea Centre for Health Economics, School of Human and Health Sciences, Swansea University, Wales, United Kingdom
    PLoS ONE 10:e0117334. 2015

Detail Information

Publications6

  1. doi request reprint The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States
    Phil McEwan
    Centre for Health Economics, Swansea University, Wales, UK Health Economics and Outcomes Research Ltd, Wales, UK
    Hepatology 58:54-64. 2013
    ..5 billion and 59,035 fewer HCV-related complications. Total QALYs and complications avoided are maximized when treatment initiation occurs as soon as possible after testing...
  2. doi request reprint Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
    Phil McEwan
    Centre for Health Economics, Swansea University, Wales, UK
    Appl Health Econ Health Policy 11:53-63. 2013
    ..Treatment response is highly dependent upon the extent of liver fibrosis yet there is little evidence quantifying the cost effectiveness of RGT particularly conditional upon fibrosis stage...
  3. doi request reprint Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
    Phil McEwan
    Health Economics and Outcomes Research, Monmouth, Wales, UK
    Hepatol Res 46:423-33. 2016
    ....
  4. doi request reprint Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C
    Rebecca Townsend
    Cardiff Research Consortium, Cardiff, Wales, UK
    Value Health 14:1068-77. 2011
    ..This study aimed to review structural frameworks and key model parameters as reported in current economic evaluations for treatments for chronic hepatitis C, and model the impact of variability across parameters on results...
  5. doi request reprint Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration
    Phil McEwan
    Swansea Centre for Health Economics, Swansea University, Wales, UK PCM, HB Health Economics and Outcomes Research Ltd, Wales, UK PCM, JG, TW University Health Board, Llandough, Wales, UK ME Global Health Economics and Outcomes Research, AstraZeneca, Molndal, Sweden KB Department of Public Health, University of Adelaide, South Australia, Australia JG
    Med Decis Making 35:660-70. 2015
    ..The objective of this study was to assess the relationship between therapy escalation threshold and time to therapy escalation on predicted cost-effectiveness of T2DM treatments...
  6. pmc Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C
    Phil McEwan
    HEOR Ltd, Singleton Court Business Park, Monmouth, Wales, United Kingdom Swansea Centre for Health Economics, School of Human and Health Sciences, Swansea University, Wales, United Kingdom
    PLoS ONE 10:e0117334. 2015
    ..The objective of this study was to quantify the clinical and economic benefit associated with increasing levels of SVR...